Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib in Newly Diagnosed GBM
NCT00720356Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Jul 2009
- Primary completion
- Jun 2014
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and erlotinib in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Northwestern University. Primary endpoint: Overall Survival. Started Jul 2009; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00720356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00720356.